Pulsatile Electrical Impedance Tomography for Diagnosis and Monitoring of Acute Pulmonary Embolism (EIT-PE)
A Multicenter Retrospective and Prospective Diagnostic Observational Study of Pulsatile Electrical Impedance Tomography for Diagnosis, Risk Stratification, and Dynamic Monitoring of Acute Pulmonary Embolism
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
Pulmonary embolism is an important type of venous thromboembolism and may be associated with substantial morbidity and mortality. CT pulmonary angiography is commonly used as the reference standard for diagnosis, but it has limitations, including radiation exposure, use of iodinated contrast agents, and limited feasibility for continuous bedside monitoring in some critically ill patients.
Electrical impedance tomography is a noninvasive functional imaging technique that can be performed at the bedside and does not involve radiation. This study will evaluate a pulsatile EIT-based approach for assessing pulmonary ventilation and perfusion. The main EIT-derived parameters include the ventilation-perfusion matching index, dead-space ventilation index, and intrapulmonary shunt index.
The retrospective phase will collect existing clinical and EIT data from patients with CTPA-confirmed acute pulmonary embolism and healthy controls. These data will be used to compare EIT parameters between groups, evaluate diagnostic performance, and explore optimal cutoff values.
The prospective phase will enroll patients newly diagnosed with acute pulmonary embolism and healthy volunteers. EIT examinations will be performed during routine clinical evaluation and follow-up. EIT parameters will be compared with CTPA findings, clinical risk stratification, D-dimer levels, echocardiographic indicators, and clinical outcomes. For patients with pulmonary embolism, serial EIT measurements may be used to evaluate dynamic changes during treatment and follow-up.
This is an observational study. Participants will not be assigned to any treatment by the study protocol, and clinical management will be determined by the treating physicians according to routine clinical practice.
Studietype
Inschrijving (Geschat)
Contacten en locaties
Studiecontact
- Naam: jiazheng LI, MD
- Telefoonnummer: +86-18810886832
- E-mail: ljzs00357@btch.edu.cn
Studie Contact Back-up
- Naam: weiwei wu, MD
- Telefoonnummer: +86-13426397036
- E-mail: weiwei.wu@btch.edu.cn
Studie Locaties
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, China, 102218
- Nog niet aan het werven
- Beijing Tsinghua Changgung Hospital
-
Contact:
- jiazheng LI, MD
- Telefoonnummer: +86-18810886832
- E-mail: ljzs00357@btch.edu.cn
-
Contact:
- weiwei wu, MD
- Telefoonnummer: +86-13426397036
- E-mail: weiwei.wu@btch.edu.cn
-
Hoofdonderzoeker:
- weiwei wu, MD
-
Beijing, Beijing Municipality, China, 100730
- Nog niet aan het werven
- Peking Union Medical College Hospital
-
Contact:
- YUN LONG, MD
- Telefoonnummer: +86-10-69155707
- E-mail: 2801634102@qq.com
-
Onderonderzoeker:
- yun long, MD
-
-
Hunan
-
Chenzhou, Hunan, China, 423000
- Werving
- Chenzhou First People's Hospital
-
Contact:
- shaofei xu, MD
- Telefoonnummer: +86-13617356697
- E-mail: 742025632@qq.com
-
Contact:
- E-mail: 742025632@qq.com
-
Onderonderzoeker:
- shaofei xu, MD
-
Loudi, Hunan, China, 417000
- Nog niet aan het werven
- Loudi Central Hospital
-
Contact:
- junbiao huang, MD
- Telefoonnummer: +8618873820320
- E-mail: 695997696@qq.com
-
Onderonderzoeker:
- junbiao huang, MD
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Bemonsteringsmethode
Studie Bevolking
Beschrijving
Inclusion Criteria:
- Adults aged 18 years or older. For retrospective PE cases: patients with acute pulmonary embolism confirmed by CT pulmonary angiography, with completed pulsatile electrical impedance tomography examination, adequate image data, and available clinical information.
For retrospective healthy controls: adults without evidence of lower-extremity venous thrombosis, with normal D-dimer levels, simplified Wells score ≤1, and no pulmonary embolism-related symptoms or history.
For prospective PE patients: patients newly diagnosed with pulmonary embolism by CT pulmonary angiography or CT pulmonary angiography plus CT venography, with body mass index less than 50 kg/m², who voluntarily participate and provide written informed consent.
For prospective non-PE controls: patients with suspected acute pulmonary embolism who undergo CT pulmonary angiography or CT pulmonary angiography plus CT venography, but in whom pulmonary embolism is not confirmed, who voluntarily participate and provide written informed consent.
Exclusion Criteria:
- Previous diagnosis of chronic pulmonary embolism or idiopathic pulmonary arterial hypertension.
Acute exacerbation of chronic obstructive pulmonary disease, acute heart failure, acute myocardial infarction, or other severe cardiopulmonary diseases that may interfere with study assessment.
Pregnancy or lactation. Thoracic deformity. Contraindications to EIT examination, including automatic implantable cardioverter defibrillator, chest wounds limiting electrode belt placement, implanted pumps, or other conditions unsuitable for EIT electrode belt placement.
Participation in another clinical trial during the same period, for prospective participants.
Unstable vital signs requiring emergency rescue, leaving no time to complete EIT examination, for prospective participants.
Any other condition considered unsuitable for participation by the investigators.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
Cohorten en interventies
Groep / Cohort |
Interventie / Behandeling |
|---|---|
|
Retrospective PE Cases
Patients aged 18 years or older with acute pulmonary embolism confirmed by CT pulmonary angiography, with completed pulsatile electrical impedance tomography examination and available clinical data in the retrospective phase.
|
Pulsatile electrical impedance tomography will be used to obtain EIT-derived parameters, including the ventilation-perfusion matching index, dead-space ventilation index, and intrapulmonary shunt index.
These parameters will be compared with CT pulmonary angiography and clinical indicators to evaluate the diagnostic performance, risk stratification value, and dynamic monitoring value of EIT in acute pulmonary embolism.
This diagnostic assessment does not assign participants to treatment and does not alter routine clinical management.
Andere namen:
|
|
Retrospective Healthy Controls
Adults in the retrospective phase without evidence of lower-extremity venous thrombosis, with normal D-dimer levels, simplified Wells score ≤1, and no pulmonary embolism-related symptoms or history.
|
Pulsatile electrical impedance tomography will be used to obtain EIT-derived parameters, including the ventilation-perfusion matching index, dead-space ventilation index, and intrapulmonary shunt index.
These parameters will be compared with CT pulmonary angiography and clinical indicators to evaluate the diagnostic performance, risk stratification value, and dynamic monitoring value of EIT in acute pulmonary embolism.
This diagnostic assessment does not assign participants to treatment and does not alter routine clinical management.
Andere namen:
|
|
Prospective PE Patients
Patients aged 18 years or older newly diagnosed with pulmonary embolism by CT pulmonary angiography or CT pulmonary angiography plus CT venography, who voluntarily participate and provide written informed consent.
|
Pulsatile electrical impedance tomography will be used to obtain EIT-derived parameters, including the ventilation-perfusion matching index, dead-space ventilation index, and intrapulmonary shunt index.
These parameters will be compared with CT pulmonary angiography and clinical indicators to evaluate the diagnostic performance, risk stratification value, and dynamic monitoring value of EIT in acute pulmonary embolism.
This diagnostic assessment does not assign participants to treatment and does not alter routine clinical management.
Andere namen:
|
|
Prospective Non-PE Controls
Patients aged 18 years or older with suspected acute pulmonary embolism who undergo CT pulmonary angiography or CT pulmonary angiography plus CT venography, but in whom pulmonary embolism is not confirmed.
These participants voluntarily participate and provide written informed consent in the prospective phase.
|
Pulsatile electrical impedance tomography will be used to obtain EIT-derived parameters, including the ventilation-perfusion matching index, dead-space ventilation index, and intrapulmonary shunt index.
These parameters will be compared with CT pulmonary angiography and clinical indicators to evaluate the diagnostic performance, risk stratification value, and dynamic monitoring value of EIT in acute pulmonary embolism.
This diagnostic assessment does not assign participants to treatment and does not alter routine clinical management.
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Diagnostic performance of EIT-derived MI, DI, and SI for acute pulmonary embolism
Tijdsspanne: At baseline or index EIT assessment
|
The diagnostic performance of EIT-derived ventilation-perfusion matching index, dead-space ventilation index, and intrapulmonary shunt index for distinguishing acute pulmonary embolism from non-PE controls will be evaluated using the area under the receiver operating characteristic curve, sensitivity, specificity, positive predictive value, negative predictive value, and optimal cutoff values, with CT pulmonary angiography as the reference standard.
|
At baseline or index EIT assessment
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Correlation between EIT-derived parameters and CTPA embolic burden
Tijdsspanne: At baseline or index assessment
|
The correlation between MI, DI, SI and the embolic burden assessed by CT pulmonary angiography will be analyzed.
|
At baseline or index assessment
|
|
Differences in EIT-derived parameters across thrombus locations and clinical risk strata
Tijdsspanne: At baseline or index assessment
|
MI, DI, and SI will be compared among patients with different thrombus locations and different clinical risk strata.
|
At baseline or index assessment
|
|
Correlation between EIT-derived parameters and clinical indicators
Tijdsspanne: At baseline or index assessment
|
The correlation between MI, DI, SI and clinical indicators, including D-dimer levels and echocardiographic indicators of right heart function, will be analyzed.
|
At baseline or index assessment
|
|
Dynamic changes in EIT-derived parameters during treatment and follow-up
Tijdsspanne: Baseline, 48 hours after thrombolytic treatment when applicable, before discharge, and 1 month after discharge
|
Changes and percentage changes in MI, DI, and SI will be assessed at baseline, during treatment when applicable, before discharge, and at 1 month after discharge.
|
Baseline, 48 hours after thrombolytic treatment when applicable, before discharge, and 1 month after discharge
|
Medewerkers en onderzoekers
Medewerkers
Onderzoekers
- Hoofdonderzoeker: weiwei Wu, MD, Beijing Tsinghua Changgeng Hospital
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Andere studie-ID-nummers
- 2D-EIT-PE-2026
- L246021 (Ander subsidie-/financieringsnummer: Beijing Natural Science Foundation-Daxing Innovation Joint Fund)
- 26890-0-01 (Andere identificatie: Institutional Review Board of Beijing Tsinghua Changgung Hospital)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .